Xencor (XNCR) Equity Average (2014 - 2026)
Xencor (XNCR) reported Equity Average of $575.6 million for Q1 2026, down 12.38% year-over-year from $656.9 million in Q1 2025, and down 8.7% quarter-over-quarter from $630.5 million in Q4 2025.
Xencor (XNCR) Equity Average (2014 - 2026) Analysis & Trends
Xencor (XNCR) has 13 years of Equity Average data on file, last reported at $575.6 million in Q1 2026.
- Equity Average for Q1 2026 came in at $575.6 million, down 12.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $575.6 million (down 12.38% YoY), and the FY2025 annual result was $654.8 million, down 1.98% from the prior year.
- Equity Average retreated to $575.6 million in Q1 2026 per XNCR's latest filing, from $630.5 million in the prior quarter.
- Over five years, Equity Average peaked at $752.7 million in Q2 2022 and troughed at $574.2 million in Q2 2024.
- A 5-year average of $666.1 million and a median of $665.5 million in 2023 frame the typical range for Equity Average.
- The sharpest annual moves came in 2022 and 2024: Equity Average rose 29.45% in 2022, then decreased 15.71% in 2024.
- A 5-year view of Equity Average shows it stood at $725.1 million in 2022, then declined by 8.21% to $665.5 million in 2023, then increased by 3.67% to $690.0 million in 2024, then retreated by 8.63% to $630.5 million in 2025, then decreased by 8.7% to $575.6 million in 2026.
- Business Quant data shows XNCR's Equity Average at $575.6 million in Q1 2026, $630.5 million in Q4 2025, and $622.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 575.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 575.61 Mn |
| Dec 31, 2025 | 630.45 Mn |
| Sep 30, 2025 | 622.83 Mn |
| Jun 30, 2025 | 630.11 Mn |
| Mar 31, 2025 | 656.95 Mn |
| Dec 31, 2024 | 689.98 Mn |
| Sep 30, 2024 | 627.32 Mn |
| Jun 30, 2024 | 574.22 Mn |
| Mar 31, 2024 | 630.91 Mn |
| Dec 31, 2023 | 665.55 Mn |
| Sep 30, 2023 | 673.94 Mn |
| Jun 30, 2023 | 681.23 Mn |
| Mar 31, 2023 | 705.54 Mn |
| Dec 31, 2022 | 725.10 Mn |
| Sep 30, 2022 | 732.52 Mn |
| Jun 30, 2022 | 752.68 Mn |
| Mar 31, 2022 | 748.26 Mn |
| Dec 31, 2021 | 676.18 Mn |
| Sep 30, 2021 | 632.90 Mn |
| Jun 30, 2021 | 615.28 Mn |